VivoSeq
Oncology

Metastatic Gastric Adenocarcinoma

8

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Metastatic Gastric Adenocarcinoma is an early-stage landscape with 8 programs across 7 companies. The most active players are Avyxa, BeiGene, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 2BeiGene logo

BeiGene

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Teva logo

Teva

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 88% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Multi-center, Non-randomized, Three-cohort, Phase II Trial of a Modified Triplet Combination of Docetaxel, Oxaliplatin and Fluorouracil for Gastric Cancer With Peritoneal Carcinomatosis and Inoperable Malignant Bowel Obstruction
Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04840264·79 enrolled
A Phase 3, Multi-Center, Randomized, Open-Label Clinical Study of Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·BBeOne Medicines·Phase 3·NCT07043400·351 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)